Colorcon

Colorcon is a company focused on the design and development of specialty excipients and film coatings tailored for solid oral dosage forms in the pharmaceutical and nutritional industries. It manufactures technologies and specialty chemicals that cater to various markets, including prescription and over-the-counter drugs, nutritional supplements, and veterinary products. By providing innovative excipients and coatings, Colorcon aims to enhance the performance and appearance of solid oral dosage forms while ensuring cost-effectiveness. The company plays a critical role in supporting the development of effective pharmaceutical and nutraceutical solutions.

Kelly Boyer

Executive

10 past transactions

Vedanta Biosciences

Venture Round in 2024
Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Mend

Series A in 2023
MEND is a life sciences company dedicated to improving health outcomes through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that aid in healing from injuries, surgeries, and illness, as well as enhancing physical performance and addressing the challenges of aging. MEND's innovations have gained acceptance in various sectors, including hospitals, health systems, professional sports teams across major leagues, and elite military forces in the United States. The company's commitment to ongoing research and development positions it as a key player in the field of clinical nutritional products, aimed at enabling caregivers to support patients in achieving optimal health and recovery.

Airnov Healthcare Packaging

Acquisition in 2023
Airnov Healthcare Packaging is a manufacturer focused on providing advanced packaging solutions for the pharmaceutical, diagnostic, nutraceutical, and health supplement sectors. The company specializes in desiccant and oxygen scavenging technologies, which are essential for protecting products from moisture, oxygen, and odors. Airnov's offerings include customizable drop-in products such as canisters and packets, integrated desiccant systems, and specially designed plastic bottles that incorporate oxygen barrier materials. By employing innovative functional design and active materials, Airnov enables its clients to maintain the potency, stability, and shelf life of their products, ensuring that they meet the high standards required in the healthcare industry.

Syntis Bio

Venture Round in 2023
Syntis Bio is a late-stage preclinical company developing novel oral therapies targeting specific tissues. Its drug formulations aim to enhance bioavailability, focusing on treatments for obesity, diabetes, and rare diseases.

Novome Biotechnologies

Series B in 2022
Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

Apprentice.io

Series C in 2022
Apprentice FS, Inc. offers an industrial augmented reality platform tailored for research and development, as well as manufacturing sectors, particularly within the life sciences. Founded in 2014 and based in Jersey City, New Jersey, the company provides an intelligent manufacturing execution system that incorporates artificial intelligence and augmented reality technologies. Its platform features modules such as Tandem, Manuals, and BioCapture, which are compatible with various smart glasses and facilitate hands-free operation in laboratory and manufacturing environments. This system allows users to record data, manage batch records, and oversee assays and procedures while ensuring critical information is readily available, thereby minimizing process deviations. Apprentice serves a range of industries, including pharmaceuticals, biotech, chemicals, consumer goods, and cosmetics, aiming to enhance efficiency and speed in drug production and other processes.

VeriSIM Life

Series A in 2022
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. It develops disease-specific biosimulation models to simulate how a drug interacts in biological systems, supporting preclinical and clinical programs. Its BIOiSIM platform covers small molecules, large molecules, and viruses, using AI-driven biosystem simulations to inform drug design, optimize development timelines, and reduce animal testing. The company aims to accelerate drug development and enable more personalized healthcare.

Ideal Cures

Acquisition in 2021
Ideal Cures Pvt. Ltd. is the world’s leading manufacturer and exporter of pharmaceutical excipients and ready-to-use coating systems for solid oral dosage forms. The product portfolio comprises INSTACOAT ready-to-use film coating systems, INSTANUTE coating technology for nutraceuticals and dietary supplements, ECOPOL range of Pharma Acrylic Polymer’s, ECOCOOL brand of cooling compounds, ESPHERES range of sugar, MCC, silicon & calcium carbonate spheres. We have three manufacturing plants located in India at Vasai, Jammu and Khambat along with two modern R&D facilities at Mumbai and Vasai. Our state-of-the-art manufacturing facilities are strongly backed by our technical services, value added products and global regulatory support including maintenance of US Drug Master Files for almost all our products. Our highly qualified and experienced technical team provides technical support to the customers whenever required.

Nourished

Venture Round in 2021
Nourished is a tech start-up that is transforming the nutrition industry with its innovative approach to personalized supplementation. The company specializes in 3D-printed vitamin stacks that are customized to meet the individual health and lifestyle needs of each customer. Utilizing patented 3D printing technology and a unique vegan encapsulation formula, Nourished combines seven high-impact nutrients, superfoods, and vitamins into a single, tasty gummy stack. The products are freshly made-to-order, ensuring maximum efficacy and optimal absorption while minimizing waste and cost. Additionally, Nourished emphasizes sustainability by using 100% plastic-free packaging and premium, sugar-free, vegan ingredients, making their offerings beneficial for both consumers and the environment.

Atomwise

Series B in 2020
Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.